Physician profile
Robert E Hosse
NPI 1447791686
$408.68
in general payments reported to CMS, 2019-2025
14 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.18 · 2024: $81.23 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.12 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $52.24 | 2024-2025 | Prolastin-C Liquid |
| Insmed, INC. | $45.37 | 2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.09 | 2024-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $39.44 | 2025 | Tezspire |
| Genzyme Corporation | $36.93 | 2024 | |
| Abbvie INC. | $30.87 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $29.74 | 2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $28.95 | 2025 | Dupixent |
| Viatris Specialty LLC | $22.98 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $19.05 | 2025 | Nucala |
| Paratek Pharmaceuticals, INC. | $18.45 | 2020 | |
| Scpharmaceuticals INC. | $16.40 | 2025 | |
| Philips North America LLC | $15.35 | 2025 | Vest Therapy Und |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hosse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.